Earnings Feed
Start Free
Home/Filings/4/0000914062-14-000081
4//SEC Filing

GALECTIN THERAPEUTICS INC 4

Accession 0000914062-14-000081

$GALTCIK 0001133416operating
View on SEC.govCompany Profile

Filed

Jan 28, 7:00 PM ET

Accepted

Jan 29, 5:08 PM ET

Size

42.2 KB

Accession

0000914062-14-000081

Insider Transaction Report

Form 4
Period: 2014-01-27
GALECTIN THERAPEUTICS INCGALT
Martin Rod D
Director10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+54,166$162,498→ 2,413,685 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+51,666$154,998→ 2,465,351 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−33,333→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2009-06-30Exp: 2019-06-30→ Common Stock (33,333 underlying)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+54,167$162,501→ 2,519,518 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+54,167$162,501→ 2,573,685 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+51,667$155,001→ 2,681,186 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+50,000$150,000→ 2,359,519 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+33,333$99,999→ 2,309,519 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+55,834$167,502→ 2,629,519 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Common Stock

    2014-01-27$3.00/sh+95,000$285,000→ 2,776,186 total(indirect: By 10X Fund, L.P.)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−54,166→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2009-09-30Exp: 2019-09-30→ Common Stock (54,166 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−51,666→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2009-11-03Exp: 2019-11-03→ Common Stock (51,666 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−54,167→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2009-12-08Exp: 2019-12-08→ Common Stock (54,167 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−54,167→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2010-01-29Exp: 2020-01-29→ Common Stock (54,167 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−55,834→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2010-03-08Exp: 2020-03-08→ Common Stock (55,834 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−51,667→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2010-04-30Exp: 2020-04-30→ Common Stock (51,667 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−95,000→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2010-05-10Exp: 2020-05-10→ Common Stock (95,000 underlying)
  • Exercise/Conversion

    Class A-2 Warrant (Right to Buy)

    2014-01-27−50,000→ 0 total(indirect: By 10X Fund, L.P.)
    Exercise: $3.00From: 2009-08-12Exp: 2019-08-12→ Common Stock (50,000 underlying)
Holdings

  • Common Stock

    91,488
Footnotes (11)
  • [F1]Amount reflects the Issuer's March 23, 2012 one-for-six reverse stock split. This filing amends all previous filings since the reverse stock split to reflect post-split beneficial holdings.
  • [F10]On April 30, 2010, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,667 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 51,667 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $310,000.
  • [F11]On May 10, 2010, 10X Fund, L.P. purchased (a) 285,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 95,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 95,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 380,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $570,000.
  • [F2]Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  • [F3]On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $500,000.
  • [F4]On August 12, 2009, 10X Fund, L.P. purchased (a) 150,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 50,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 50,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 200,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $300,000.
  • [F5]On September 30, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,166 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,166 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,666 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
  • [F6]On November 3, 2009, 10X Fund, L.P. purchased (a) 155,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 51,666 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 51,666 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 206,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $310,000.
  • [F7]On December 8, 2009, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
  • [F8]On January 29, 2010, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 54,167 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 216,667 shares of Common Stock for $3.00 per share, for aggregate consideration of $325,000.
  • [F9]On March 8, 2010, 10X Fund, L.P. purchased (a) 167,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 55,834 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 55,834 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 223,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $335,000.

Documents

1 file

Issuer

GALECTIN THERAPEUTICS INC

CIK 0001133416

→
Entity typeoperating
IncorporatedNV

Related Parties

1
  • filerCIK 0001133416

Filing Metadata

Form type
4
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 5:08 PM ET
Size
42.2 KB
View on SEC.gov